Synageva Scientific and Corporate Advisors

Synageva has a scientific advisory board specific to sebelipase alfa (SBC-102) and SBC-103 which includes many of the world’s thought leaders in the areas of Lysosomal Storage Disorders, hepatology, lipid disorders and enzyme replacement therapies.

We also have Scientific and Corporate Advisors that counsel the company on corporate strategy and research and development and commercial vision efforts.


Our Scientific and Corporate Advisors include:


Robert J. Desnick, MD, PhD

Dean for Genetic and Genomic Medicine
Professor and Chairman Emeritus

Department of Genetics and Genomic Sciences
Icahn School of Medicine at Mount Sinai